ChiCTR2500101649 版本V1.0 版本创建时间2025/04/28 09:05:56 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500101649 

最近更新日期:

Date of Last Refreshed on:

2025-04-28 09:05:50 

注册时间:

Date of Registration:

2025-04-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

围术期口服营养制剂对老年患者关节置换术后应激及早期功能康复的影响:一项前瞻性随机对照试验

Public title:

Effects of oral nutrition preparation on stress and early functional rehabilitation of elderly patients after total joint arthroplasty: a prospective randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

围术期口服营养制剂对老年患者关节置换术后应激及早期功能康复的影响:一项前瞻性随机对照试验

Scientific title:

Effects of oral nutrition preparation on stress and early functional rehabilitation of elderly patients after total joint arthroplasty: a prospective randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李乾浩 

研究负责人:

康鹏德 

Applicant:

Li Qianhao 

Study leader:

Kang Pengde 

申请注册联系人电话:

Applicant telephone:

+86 183 4911 5976

研究负责人电话:

Study leader's telephone:

+86 189 8060 1953

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liqianhao2008@163.com

研究负责人电子邮件:

Study leader's E-mail:

liqianhao2008@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市武侯区国学巷37号

研究负责人通讯地址:

四川省成都市武侯区国学巷37号

Applicant address:

No.37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan, Province

Study leader's address:

No.37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan, Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西医院

Applicant's institution:

West China Hospital of Sichuan University

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West China Hospital of Sichuan University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024年审(2493)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理审查委员会

Name of the ethic committee:

West China Hospital of Sichuan University Biomedical Research Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2025-04-21 00:00:00

伦理委员会联系人:

邓绍林

Contact Name of the ethic committee:

Deng Shaolin

伦理委员会联系地址:

四川省成都市武侯区国学巷37号

Contact Address of the ethic committee:

No.37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan, Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 183 4911 5976

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital of Sichuan University

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

No.37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan, Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

Country:

China

Province:

Sichuan

City:

单位(医院):

四川大学华西医院

具体地址:

四川省成都市武侯区国学巷37号

Institution
hospital:

West China Hospital of Sichuan University

Address:

No.37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan, Province

经费或物资来源:

自筹

Source(s) of funding:

Self-raised funds

Target disease:

Bone and joint diseases

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.主要目标:研究肠内营养制剂在老年患者TJA术后肌肉质量及早期功能康复干预效果 2.次要目标:研究肠内营养制剂对老年患者TJA术后应激反应及并发症发生的影响  

Objectives of Study:

1. To study the effect of enteral nutrition preparation on muscle mass and early functional rehabilitation in elderly patients after TJA. 2. To study the effect of enteral nutrition preparation on stress response and complications of elderly patients after TJA.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.因重度骨关节炎(K-L III-IV级)需行初次单侧TJA患者; 2.年龄≥60岁; 3.ASA分级I-III级; 4.BMI 18.5-28 kg/m^2; 5.患者半年内未常规服用蛋白粉等营养制剂。

Inclusion criteria

1.Patients who need to undergo unilateral TJA for the first time because of severe osteoarthritis (K-L III-IV grade); 2.Age >=60 years old; 3.ASA classification I-III; 4.BMI 18.5-28 kg/m^2; 5.The patient did not routinely take nutritional preparations such as protein powder for half a year.

排除标准:

1.关节外伤、感染、既往手术史等病史; 2.糖尿病、严重心肺疾病、肝肾功能障碍、精神病史等; 3.胃肠张力下降、严重消化不良或吸收不良、消化道出血等胃肠道疾病; 4.对本研究所用营养制剂过敏反应等。

Exclusion criteria:

1.Joint trauma, infection, previous surgical history and other medical history; 2.Diabetes, serious heart and lung diseases, liver and kidney dysfunction, mental history, etc.; 3.Gastrointestinal diseases such as decreased gastrointestinal tension, severe dyspepsia or malabsorption, and gastrointestinal bleeding; 4.Allergic reactions to nutritional preparations used in this study.

研究实施时间:

Study execute time:

From 2025-04-30 00:00:00 To 2026-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-05-12 00:00:00 To 2026-04-30 00:00:00  

干预措施:

Interventions:

组别:

研究组

样本量:

40

Group:

Research group

Sample size:

干预措施:

患者围术期口服营养制剂200ml/天(主要含碳水化合物20.8g、蛋白质11.7g、不饱和脂肪酸8.6g、膳食纤维6.5g,能量260kcal)

干预措施代码:

Intervention:

Perioperative oral nutrition preparation was 200ml/ day (mainly containing carbohydrate 20.8g, protein 11.7g, unsaturated fatty acid 8.6g, dietary fiber 6.5g, energy 260kcal).

Intervention code:

组别:

对照组

样本量:

40

Group:

Control group

Sample size:

干预措施:

患者不口服营养制剂

干预措施代码:

Intervention:

Without oral nutrition preparations.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

 

Country:

China 

Province:

Sichuan 

City:

 

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

West China Hospital of Sichuan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

炎症指标

指标类型:

主要指标

Outcome:

Inflammation index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胰岛素抵抗指标

指标类型:

主要指标

Outcome:

Insulin resistance index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规及血生化

指标类型:

主要指标

Outcome:

Blood routine and blood biochemistry

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

免疫指标

指标类型:

主要指标

Outcome:

Immune index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

功能指标

指标类型:

主要指标

Outcome:

Functional index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术中情况

指标类型:

次要指标

Outcome:

Intraoperative situation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症

指标类型:

副作用指标

Outcome:

Complication

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究人员1在患者干预前使用计算机生成的随机数字列表,将患者随机分至研究组或对照组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Researcher 1 used a computer-generated random number list to randomly divide patients into study group or control group before intervention.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

单盲

Blinding:

Single blind

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF表+HIS系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF+HIS

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-04-28 09:05:50